KRAS and acute myeloid leukemia: After aggregating these datasets, mutations were represented in similar proportions as in the TCGA (20) and BeatAML (21) studies, except for enrichment in mutations common in AML, such as in NPM1 and FLT3, and in low-level signaling mutations (Supplementary Figure 7A); for instance, 58% of KRAS mutations were in <10% of the corresponding sample’s cells.